about
Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers.Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.Chemopotentiation by PARP inhibitors in cancer therapy.Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving TargetsRecent approaches to improve the antitumor efficacy of temozolomide.Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant.Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor GrowthAntitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.Challenging resistance mechanisms to therapies for metastatic melanoma.A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.Exploiting Microglial Functions for the Treatment of Glioblastoma.Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin.Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness.MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.Thymic selection of the T-cell repertoire.Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype.Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin.N3-methyladenine induces early poly(ADP-ribosylation), reduction of nuclear factor-kappa B DNA binding ability, and nuclear up-regulation of telomerase activity.Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen.The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cellsModulation of GDF11 expression and synaptic plasticity by age and training.Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes.Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.Primary cultures of microglial cells for testing toxicity of anticancer drugs.Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine.Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma.Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide.The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo.Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic AcidIn vitro antitumor activity of 3′-desamino-3′(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds
P50
Q34234110-29F58E5C-2E1A-4C11-ADDE-E3D096593197Q34532469-7C7A7D29-D7C5-4998-96E5-4C3BFCBF6334Q35110170-4EF4B766-0B39-4008-84A5-F8E3A2E471B5Q36136079-592685B8-D727-43AE-AFDD-67E35D9E8878Q36756258-981655F4-A439-49F7-9F0A-9A043810BD70Q37307055-13AB067B-4223-437F-BA01-8FA086CBEB82Q37370405-4E471E18-D9EB-47BD-852A-396B705AA690Q37421089-8368D46F-B819-468D-B04E-87B1D9FAE9C8Q37463406-7C252C37-AC52-4B22-A5DD-85FCD1C7B9EDQ37687310-73C0F128-3FC0-4A52-93C8-FBBE144212E1Q37935254-06A9BF83-FB79-4E37-87F8-716E3E262B8AQ38161180-16C0BCA7-AC15-4580-B86C-868A6891B0AAQ38896939-71C9F3FA-ABBA-4E86-B168-BFBB36353893Q38928517-06C7FFEC-2463-430F-A678-302BE6D1412FQ38950364-565F4A00-8FDF-4499-BDC0-3CC883F46C87Q39078357-41319F54-0B14-4B9C-92B9-24E9F5D6876FQ39157632-081D2B45-5F11-4498-9F4B-1F51284571A6Q39602310-506719A3-98AA-4874-8511-91200540CB03Q39608882-19661CF8-36A9-4939-9F62-08F6E5D25A6BQ40209766-C3B1AA9E-46F0-4C75-862B-1C08C07E4554Q40351208-5868F81D-5812-45BB-ADDD-6657C9482BE6Q40378448-CC65C786-F411-4196-A780-082CAAA0D528Q40490577-EC466022-6D3E-4525-B4A4-D0612F989B93Q40700534-D38043FE-5808-4F30-8E5D-972FA09A6020Q40807059-FD83EBB1-C2DA-49BC-AD45-E08DF6A394BAQ41006776-66BC080D-0049-4547-8954-34315525CF6EQ41364759-9A9CF2F9-9B38-4030-B5C6-9B8F719F60D2Q41708656-3EA6FB35-AB16-4070-8546-7D06D9EBEF8AQ42434815-D5B0F5BB-46AC-4974-BD89-43D8E6A0CCFAQ43904548-506EEDFA-7A17-486C-82D9-40EFD4C545C5Q43949121-96B9EF01-46AF-4077-A1B4-F5542C21845EQ44141707-87A7D9C0-507C-47D3-86C7-2A20036E73C0Q44798564-B8B523EC-D63E-40C8-B38D-EB1E26419483Q45180583-8EFF7ECB-D888-412D-94F7-CD45493441C2Q45362769-88D5ED2E-8A53-4BC5-A913-877BF3F5FEEAQ47408825-3AF1236A-5FF4-41A7-B2F8-891872190935Q47593215-E95BF0DE-69E0-46D7-806E-B08E7844EABAQ47660175-880E4F83-000B-4F0D-BE07-36808141E6F6Q59807385-DC19CDED-6925-4022-84E0-0BF694398DD6Q61457971-0248D1EC-D07F-4678-B5DE-D63F23B5662F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lucio Tentori
@ast
Lucio Tentori
@en
Lucio Tentori
@es
Lucio Tentori
@nl
type
label
Lucio Tentori
@ast
Lucio Tentori
@en
Lucio Tentori
@es
Lucio Tentori
@nl
prefLabel
Lucio Tentori
@ast
Lucio Tentori
@en
Lucio Tentori
@es
Lucio Tentori
@nl
P106
P1153
7005614571
P21
P31
P496
0000-0002-7691-527X